Q4 and FY2026 Results Presentation
DEEPAKNTR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Smallcap 250 and 2.8 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Deepak Nitrite reported Q4 FY26 revenue of ₹2,127 crore with a strong sequential recovery—EBITDA surged 74% Q-o-Q to ₹383 crore and PAT jumped 120% Q-o-Q to ₹220 crore. However, full-year FY26 shows declining performance: revenue fell 5% to ₹7,947 crore, EBITDA dropped 11% to ₹1,041 crore, and PAT declined 21% to ₹551 crore compared to FY25. Q4 EBITDA margin expanded significantly to 18% from 11% in Q3, driven by cost optimization, favourable product mix, and pricing gains in both Advanced Intermediates and Phenolics segments. The company cited geopolitical disruptions and crude-linked supply chain volatility as challenges but highlighted successful supply chain resilience initiatives including long-term feedstock agreements and backward integration projects.
The sharp Q4 recovery suggests improving operational efficiency and margin resilience despite challenging global conditions. While FY26 full-year declines reflect ongoing pricing pressures in the chemical industry, the margin expansion and 120% PAT growth in Q4 indicate strengthening profitability that could be positive for the stock if sustained into FY27.